contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


ascelia-pharma-continuing-to-position-itself-for-striking-a-deal-abg

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Ascelia Pharma är ett läkemedelsbolag. Bolaget är specialiserat på utveckling av särläkemedel inom onkologi (cancer). Bolaget utvecklar diverse läkemedelskandidater, där störst användning återfinns inom behandling av cancer som drabbat lever och magsäck. Bolaget grundades år 2000 och har huvudkontor i Malmö, Sverige, men är verksamt på en global marknad.

Ascelia Pharma

* An NDA for Orviglance submitted to the FDA* Patience for a partner deal* Fair value range updated: SEK 2.9-6.6 (2.6-6.9)Preparing for a US approval and partner dealAscelia delivered a quarter...

* An NDA for Orviglance submitted to the FDA* Patience for a partner deal* Fair value range updated: SEK 2.9-6.6 (2.6-6.9)Preparing for a US approval and partner dealAscelia delivered a quarter largely in line with expectations, with operating CF at SEK -16m (SEK -18m in Q2) and cash and cash equivalents at SEK 72m (SEK 60m in Q2) after a directed share issue of net ~SEK 28m, and Fenja Capital's conversion of all outstanding convertibles of SEK 7.5m. Positively, opex decreased by ~35% and ~15% q-o-q and y-o-y, respectively. Following this, Ascelia expects a cash runway into Q4'26e, excluding potential partner revenues. Importantly, the New Drug Application (NDA) submission to the FDA for the MRI contrast agent Orviglance was submitted in early September. Ascelia expects a standard ten months review time, leading to an anticipated approval in July '26. This comes after the pivotal Ph 3 SPARKLE trial successfully met its primary endpoint, demonstrating that the company’s MRI contrast agent Orviglance significantly (p &lt; 0.001) improved the visualisation of metastatic liver lesions compared to un-enhanced MRI.Estimate revisionsAs before, we model that Orviglance will be commercialised through a partner - in line with sustained company guidance. We make the following estimate revisions to our model: i) A partner deal for Orviglance is delayed until '26e, which as before is accompanied by a USD 10m upfront payment; ii) A European launch is delayed from early '27e to late 27'e, as this is planned to be undertaken by a partner; and iii) Commercial milestones are cut to USD 40m (USD 50m).Valuation updateThe changes listed above yield a new fair value range of SEK 2.9-6.6 (2.6-6.9), implying an attractive risk/reward. The strengthened balance sheet adds to this, particularly as it ensures sufficient funding through the key regulatory milestones and improves the company's negotiating position.